Investigating the effect of empagliflozin on water and electrolyte levels in non-dialysis chronic kidney disease patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N215

Enrollment

Registered

2024-03-10

Start date

2024-04-03

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease. Chronic kidney disease, unspecified

Interventions

Intervention 1: In the intervention group, Empagliflozin 10 mg (low dose) is prescribed every other day for one month for patients under the supervision of the expert doctor who is implementing the pr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Informed consent Patients with chronic kidney disease diagnosed by a doctor

Exclusion criteria

Exclusion criteria: History of dialysis History of autoimmune disorders and neoplasias

Design outcomes

Primary

Measure	Time frame
Clinical condition of the patient. Timepoint: Before the intervention and two months after the end of the intervention. Method of measurement: Based on the checklist and questions from the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Sima Golmohammadi

Kermanshah University of Medical Sciences

s.golmohammadi@kums.ac.ir+98 83 3427 6306

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026